Why Cassava Sciences Stock Is Trading Down Today
Portfolio Pulse from Ryan Gustafson
Cassava Sciences, Inc. (NASDAQ:SAVA) announced the top-line clinical results from its Cognition Maintenance Study where oral simufilam in patients with mild-to-moderate Alzheimer's slowed cognitive decline by 38% over 6 months. Despite the positive results, shares of SAVA were down 14.4% at $21.67.
July 05, 2023 | 5:47 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cassava Sciences' stock price fell despite positive clinical results from its Alzheimer's drug study.
Despite the announcement of positive clinical results from its Cognition Maintenance Study, Cassava Sciences' stock price fell. This could be due to a variety of factors, including market sentiment, overall market conditions, or investor expectations. The news is highly relevant to SAVA as it directly pertains to the company's operations and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100